Comera Life Sciences Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMRA research report →
About the company
Comera Life Sciences Holdings, Inc. is an early-stage biotechnology firm focused on creating its own pipeline of innovative therapies. These treatments leverage its exclusive SQore formulation platform, engineered to transform intravenous (IV) biologic drugs into more convenient subcutaneous (SQ) injectable forms.
- CEO
- Michael G. Campbell
- IPO
- 2020
- Employees
- 12
- HQ
- Woburn, MA, US
Price Chart
- Market Cap
- $3.07K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
- Gross Margin
- 66.77%
- Op Margin
- -1890.69%
- Net Margin
- -2843.79%
- ROE
- 47452.88%
- ROIC
- 1768.56%
- Revenue
- $633.10K · 97.95%
- Net Income
- $-18,004,098 · -230.24%
- EPS
- $-1.76 · -506.90%
- Op Income
- $-11,970,015
- FCF YoY
- -151.29%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -20.43
- Avg Volume
- 926
Get TickerSpark's AI analysis on CMRA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 29, 23 | Konar Shameek | buy | 4,090,908 |
| Dec 29, 23 | Konar Shameek | buy | 0 |
| Dec 27, 23 | Konar Shameek | other | 0 |
| Sep 11, 23 | Konar Shameek | other | 513,447 |
| Dec 29, 23 | DENNY GEORGE P III | buy | 3,913,526 |
| Dec 29, 23 | DENNY GEORGE P III | buy | 0 |
| Dec 27, 23 | DENNY GEORGE P III | other | 0 |
| Sep 11, 23 | DENNY GEORGE P III | other | 337,408 |
| Jan 4, 23 | DENNY GEORGE P III | other | 405,405 |
| Dec 27, 23 | HALPERN JOHN D | other | 0 |
Our CMRA coverage
Recent articles, reports, and earnings notes.
No research on CMRA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMRA report →Similar companies
Peers in the same neighborhood.